Private Advisor Group’s Compass Therapeutics CMPX Stock Holding History

Private Advisor Group’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.6K	Buy	+11,124	New	+$22.9K	﹤0.01%	3121

Other funds holding CMPX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Private Advisor Group's CMPX Position: Q3 2026 in Review

Private Advisor Group opened a new position in Compass Therapeutics (CMPX) in Q3 2026: 11,124 shares worth $11.6K. The stake represents ﹤0.01% of the portfolio and ranks #3121 among its holdings.

68 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

Private Advisor Group held 11,124 shares of Compass Therapeutics worth $11.6K as of Q3 2026.
Compass Therapeutics was a new Private Advisor Group position in Q3 2026.
Compass Therapeutics made up ﹤0.01% of Private Advisor Group's portfolio in Q3 2026, its #3121 holding.
68 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on Private Advisor Group's 13F filing for Q3 2026, filed 10 Nov 2026.